November 03, 2026

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

BSE Scrip Code No. 524280

The Manager
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

NSE Symbol: KOPRAN

Dear Sir/Madam,

Sub: Investor Presentation on Unaudited Financial Results for the quarter ended September 30, 2026.


Dear Sir / Madam,

Please find attached Investor Presentation on Unaudited Financial Results for the quarter ended September 30, 2026.

The above information will also be made available on the website of the Company www.kopran.com

Regards,
For Kopran Limited
Sunil Radheyshyam Sodhani
Digitally signed by Sunil Radheyshyam Sodhani
DN: c=IN, o=Personal, postalCode=400059, l=Mumbai Suburban, st=Maharashtra, street=1302, B16, Lilium, Vasant Oasis, Marol, Mumbai, Andheri Maharashtra India 400059, title=7249, 2.5.4.20=5cacec1af27b3e58afe7ae706769ddad331de89dbced35c287151db270caabb60, serialNumber=903718d01aa6d383c476bb9cff5d4859c7b7aa7e6a5d9dc32acceca32c46e9c75, email=sunil_sodhani@hotmail.com, cn=Sunil Radheyshyam Sodhani
Date: 2026.11.03 14:56:34 +05'30'
Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS3897
Encl.: a/a.

PARIJAT ENTERPRISES



Kopran

CORPORATE PRESENTATION

HY - 2026-27

SAFE HARBOUR STATEMENT

Kopran

This quarterly investor presentation has been prepared by Kopran Limited ('Kopran') and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be 'forward-looking statements', including those relating to the general business plans and strategy of Kopran, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation businesses.

Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

Kopran

PERFORMANCE

- Financial Highlights
- Operational Performance
- API
- Formulation

FINANCIAL HIGHLIGHTS Consolidated (Rs. in Lakhs)

Kopran

PARTICULARS	Q-2 2026-27	Q-1 2026-27	Q-2 2025-26	HY 2026-27	HY 2025-26	FY 2025-26
Revenue from Operations	21,126	15,399	11,791	36,526	25,313	68,142
Forex Gain/Loss	(219)	198	(824)	(21)	(585)	(1,595)
EBITDA*	1,822	1,588	299	3,410	1,709	7,825
Finance Costs	425	328	209	754	463	1,047
Depreciation	589	577	428	1,166	854	1,747
Tax Expenses	150	210	(170)	360	74	863
Net Profit	439	670	(992)	1,110	(247)	2,573
EBITDA Margin	8.62%	10.31%	2.53%	9.34%	6.83%	11.48%

* EBIDTA excluding other income and forex losses


OPERATIONAL PERFORMANCE

Kopran




APIs OPERATIONAL HIGHLIGHTS
SEGMENT-WISE REVENUE MIX

HY - 2026-27 (Rs. in Lakhs)



Total Rs. 21,859 Lakhs

Q2 - FY 2026-27 (Rs. in Lakhs)




Total Rs. 12,321 Lakhs

APIs

OPERATIONAL HIGHLIGHTS


MARKET-WISE REVENUE MIX

HY - 2026-27 (Rs. in Lakhs)



Total Rs. 21,859 Lakhs

Q2 - FY 2026-27 (Rs. in Lakhs)




Total Rs. 12,321 Lakhs

Formulations


OPERATIONAL HIGHLIGHTS
REGION-WISE SALES BREAK-UP

HY - 2026-27 (Rs. in Lakhs)



Total Rs. 14,131 Lakhs

Q2 - FY 2026-27 (Rs. in Lakhs)




Total Rs. 8,422 Lakhs

Formulations


OPERATIONAL HIGHLIGHTS
PRODUCT-WISE REVENUE MIX

HY - 2026-27 (Rs. in Lakhs)



Total Rs. 14,131 Lakhs

Q2 - FY 2026-27 (Rs. in Lakhs)



Total Rs. 8,422 Lakhs

Company Overview

- About Us
- Business Overview – API
- Business Overview – Formulations
- Driving Sustainable Growth

KOPRAN LIMITED A GLOBAL PHARMACEUTICAL COMPANY

Kopran

An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally.

State-of-the-art manufacturing facilities and products with various accreditations and approvals by major global regulatory authorities.

The formulations vertical is operated through Kopran Limited.

The API vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a wholly owned subsidiary of Kopran Limited

50+
Nations - Export Reach

Technology-focused Company

Serving Regulated and Non-Regulated Markets



2
State-of-the-art Manufacturing Facilities

*** Our presence across two major verticals in the pharmaceutical value chain**

BUSINESS OVERVIEW API

Kopran

API VERTICAL

- Development, manufacturing and sale of diverse APIs and Advanced Intermediates
- One of the leaders in Atenolol
- One of the major players in Sterile Carbapenems
- World-class facility and quality systems
- Catering export and domestic market

DEDICATED AND VERSATILE FACILITIES FOR

- Atenolol
- Cephalosporins - Non-Sterile & Sterile
- Macrolides
- Granules
- Sterile Carbapenems
- Multipurpose plants
- Pilot plants

PRODUCT SEGMENT

- Anti-hypertensive
- Macrolide
- Neuromodulator
- Urological
- Anti-infective/Anti-acne
- Sterile Carbapenem
- Sterile Cephalosporin
- Anti-thrombotic
- Intermediate
- Anti-Diabetic
- Cardiology
- NSAIDs
- Anti Lipid

FACILITY — Located at **MIDC Mahad, Maharashtra** — **11,900** sq. mts. built-up area

26 **Products commercialised**

BUSINESS OVERVIEW FORMULATIONS

Kopran

PRODUCT SEGMENTS

PENICILLIN-BASED FINISHED ORAL DOSAGE FORMS

- Anti-infective
- Amoxycillin
- Ampicillin
- Cloxacillin
- Amoxy Clauv

NON-PENICILLIN BASED FINISHED ORAL DOSAGE FORMS

- Macrolides
- Anti-hypertensive
- Cardiovascular
- Anti-helmentics
- Anti-histamine
- EDS
- Anti-diabetic
- CNS
- Pain Management
- Gastroenterology

FORMULATIONS VERTICAL

- Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs
- Catering 100% export markets of both Regulated and Non-Regulated markets
- Manufacturers of more than 100 dosages meeting the standards of international markets which includes Tablets, Capsules, Dry Powder and Suspension

DEDICATED FACILITIES

- Penicillin-based finished oral dosage forms
- Non-Penicillin-based finished oral dosage forms

FACILITY → Located at **Khopoli, Maharashtra** → **11,432** sq. mts. built-up area

DRIVING SUSTAINABLE GROWTH STRATEGIC IMPERATIVES

Kopran

GROWTH AND SUSTAINABILITY

- Focus on R&D to develop niche, high-value/high-volume APIs and intermediates
- Capacity expansion
- Compliance with Global Regulatory standards
- Synergies between APIs and formulations
- API and R&D facility at Panoli (Gujarat)

BALANCE PROFITABILITY & INVESTMENT FOR FUTURE

- Prudent capital allocation
- Increase asset to turnover ratio

COST LEADERSHIP

- Development of intermediates for APIs
- Reducing dependence on China to move towards self sufficiency
- Optimising operational cost
- Process improvements: Improving yields of existing products
- Atomization of packing lines in formulations

BUSINESS DEVELOPMENT

- Leveraging customer base for new products
- New customers and newer geographies
- New regulatory filings and registrations

DRIVING SUSTAINABLE GROWTH REGULATORY COMPLIANCE

Kopran

OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE

FORMULATIONS ACCREDITATIONS


Approved by 15 countries including MHRA (UK), SAPHRA South Africa (formerly MCC), MMA Malta (EU GMP), Health Canada (Canada), FDA Philippines, DAV Vietnam, FDA Thailand, TMDA Tanzania (formerly TFDA), NDA Uganda, PPB Kenya, EFDA Ethiopia, MCAZ Zimbabwe, MOH Oman, MOH Iraq, MOH Yemen



The Company maintains highest global regulatory standards of manufacturing and quality at its all plants

API ACCREDITATIONS

The plant has been approved by



***Except sterile facility**

FINANCIAL PERFORMANCE


Kopran




FINANCIAL HIGHLIGHTS SNAPSHOT

Kopran


SALES/OTHER INCOME (Rs. in LAKHS)




EBITDA * (Rs. in LAKHS)



FINANCE COSTS (Rs. in LAKHS)



EBITDA MARGIN (%)




*** Note: EBITDA excluding other Income & Forex Losses**

FINANCIAL HIGHLIGHTS


BUILDING SHAREHOLDER VALUE YEAR ON YEAR

Kopran


EBIT (Rs. in Lakhs)




RoE (%) RoCE (%)



Net Profit / Loss (Rs. in Lakhs)



Net Debt / Equity (X)



CONSOLIDATED FINANCIAL HIGHLIGHTS (Rs. in Lakhs)

Kopran

PARTICULARS	HY SEP - 2026	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity Share Capital	4,833	4,829	4,829	4,821	4,821	4,821	4,325	4,325
Other Equity	47,965	48,199	47,006	44,303	39,104	37,796	20,178	14,643
Net Worth	52,797	53,028	51,835	49,125	43,925	42,617	24,503	18,968
Fixed Assets(net)	38,972	37,124	32,160	27,830	23,457	18,623	15,508	14,139
Borrowings	20,837	15,269	14,779	9,923	7,524	7,248	6,429	7,806
Sales/Other Income	36,856	68,177	63,359	62,920	55,405	48,813	50,980	36,013
EBIDTA	1,822	7,790	7,290	7,441	5,180	8,739	8,178	4,696
Finance Costs	754	1,047	934	859	608	512	624	891
Depreciation	1,166	1,747	1,559	1,289	1,271	1,110	1,019	958
Tax Expenses	360	863	1,340	1,659	376	2,075	2,173	726
Net Profit/(loss)	1,110	2,573	3,855	5,096	2,723	6,103	6,161	2,120
Earning per share (Rs.)	2.30	5.33	7.99	10.57	5.65	13.77	14.24	4.86

Note: EBITDA excluding other income & Forex Losses

GOVERNANCE

BOARD OF DIRECTORS

Kopran



MR. SURENDRA SOMANI
CHAIRMAN & MANAGING DIRECTOR



MR. VARUN SURENDRA SOMANI
DIRECTOR



MRS. NAMRATA SOMANI
DIRECTOR



MR. CHANDRESH GANDHI
INDEPENDENT DIRECTOR



MRS. MAMTA BIYANI
INDEPENDENT DIRECTOR



MR. NARAYAN ATAL
INDEPENDENT DIRECTOR

CONTACT US

Kopran

ABOUT KOPRAN LIMITED:

Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New Products and Processes for both Formulations & APIs form the strategy of Kopran's growth.

REGISTERED OFFICE:

Parijat House, 1076, Dr. E. Moses Road,
Worli, Mumbai – 400 018,
Maharashtra (India)
Corporate Identification No.:
L24230MH1958PLC011078

For more information about us, please visit
www.kopran.com
or contact:
Name: Sunil Sodhani
Tel.: +91 8692991999
Email: sunil@kopran.com